OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
March 24, 2023
Curia is collaborating with Corning to advance biopharmaceutical continuous-flow development and manufacturing programs.
A new Interagency Working Group for Bayh-Dole will review the government’s authority to revoke licenses for medical products.
March 23, 2023
The recent document will guide the use of DHT-derived data in regulatory decision-making for drugs and biological products.
Three new awards have been added to the roster for 2023 and include some specific highlights that have occurred over the past few years.
March 22, 2023
Under a new partnership, Invitae and Deerfield Management will harness genetic and clinical testing data from patients to discover potential novel therapeutics for treating rare diseases.
In addition to a new interim president, the company is opening new microbial capacity at its San Antonio facility and has plans to construct a commercial-scale facility in Manhattan, Kan.
The combined solutions are currently available on the market.
The services are based on the company’s PurePrep EasyClean (PEC) orthogonal peptide purification technology.
The decision was based on results from the PROpel Phase III trial.
This approval makes the drug the first and only targeted medicine indicated to treat this population of children in Europe and the United States.